By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.

The Voice of People With Breast Cancer

Education

Our Voices Blog


Tag : patient safety

Biosimilars: Clinical perspective

We are all familiar with generics.  The exact copy of the known chemical formula used in the original medicine is what constitutes the generic form of any medicine.  There are multiple reasons why generics are able to be mass produced at a lower cost.  An important step includes manufacturers of generics having to provide proof that their version is an exact copy of the chemical formula of the original medicine and that when used in healthy individuals, the metabolism remains very similar to the original compound.  This shortened pathway of getting approved from Health Canada or a similar regulatory agency ensures less economic burden to manufacturers and provides the obvious advantage of a significantly lower price, as well as improved accessibility for patients.